ArticleAmerican health & drug benefits2018

Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.

Michele Wilson et al.PubMed ↗Full text ↗

No numbers read from the abstract.